These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 30585294)
1. MiR-424-3p suppresses galectin-3 expression and sensitizes ovarian cancer cells to cisplatin. Bieg D; Sypniewski D; Nowak E; Bednarek I Arch Gynecol Obstet; 2019 Apr; 299(4):1077-1087. PubMed ID: 30585294 [TBL] [Abstract][Full Text] [Related]
2. Morin decreases galectin-3 expression and sensitizes ovarian cancer cells to cisplatin. Bieg D; Sypniewski D; Nowak E; Bednarek I Arch Gynecol Obstet; 2018 Dec; 298(6):1181-1194. PubMed ID: 30267152 [TBL] [Abstract][Full Text] [Related]
3. miR-378a-3p sensitizes ovarian cancer cells to cisplatin through targeting MAPK1/GRB2. Xu ZH; Yao TZ; Liu W Biomed Pharmacother; 2018 Nov; 107():1410-1417. PubMed ID: 30257357 [TBL] [Abstract][Full Text] [Related]
4. miR-509-3p promotes cisplatin-induced apoptosis in ovarian cancer cells through the regulation of anti-apoptotic genes. Chen W; Du J; Li X; Su J; Huang Y; Ding N; Zhang M; Jiang S Pharmacogenomics; 2017 Dec; 18(18):1671-1682. PubMed ID: 29173002 [TBL] [Abstract][Full Text] [Related]
5. Effects of microRNA-1271 on ovarian cancer via inhibition of epithelial-mesenchymal transition and cisplatin resistance. Chen Y; Wang L; Zhou J J Obstet Gynaecol Res; 2019 Nov; 45(11):2243-2254. PubMed ID: 31411791 [TBL] [Abstract][Full Text] [Related]
6. Galectin-3 regulates chemotherapy sensitivity in epithelial ovarian carcinoma via regulating mitochondrial function. Wang D; You D; Li L J Toxicol Sci; 2019; 44(1):47-56. PubMed ID: 30626779 [TBL] [Abstract][Full Text] [Related]
7. miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes. Li X; Chen W; Jin Y; Xue R; Su J; Mu Z; Li J; Jiang S Biochem Pharmacol; 2019 Mar; 161():98-112. PubMed ID: 30639456 [TBL] [Abstract][Full Text] [Related]
8. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85. Wu D; Lu P; Mi X; Miao J Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155 [TBL] [Abstract][Full Text] [Related]
9. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs. Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496 [TBL] [Abstract][Full Text] [Related]
10. The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells. Pink RC; Samuel P; Massa D; Caley DP; Brooks SA; Carter DR Gynecol Oncol; 2015 Apr; 137(1):143-51. PubMed ID: 25579119 [TBL] [Abstract][Full Text] [Related]
11. miR-199a-3p enhances cisplatin sensitivity of ovarian cancer cells by targeting ITGB8. Cui Y; Wu F; Tian D; Wang T; Lu T; Huang X; Zhang P; Qin L Oncol Rep; 2018 Apr; 39(4):1649-1657. PubMed ID: 29436681 [TBL] [Abstract][Full Text] [Related]
12. Restoration of microRNA-708 sensitizes ovarian cancer cells to cisplatin via IGF2BP1/Akt pathway. Qin X; Sun L; Wang J Cell Biol Int; 2017 Oct; 41(10):1110-1118. PubMed ID: 28685895 [TBL] [Abstract][Full Text] [Related]
13. MicroRNA-155 promotes apoptosis in SKOV3, A2780, and primary cultured ovarian cancer cells. Chen W; Huang L; Hao C; Zeng W; Luo X; Li X; Zhou L; Jiang S; Chen Z; He Y Tumour Biol; 2016 Jul; 37(7):9289-99. PubMed ID: 26779627 [TBL] [Abstract][Full Text] [Related]
14. MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1. Wu DD; Li XS; Meng XN; Yan J; Zong ZH Tumour Biol; 2016 Aug; 37(8):10499-506. PubMed ID: 26850595 [TBL] [Abstract][Full Text] [Related]
15. Targeting miR-21-3p inhibits proliferation and invasion of ovarian cancer cells. Báez-Vega PM; Echevarría Vargas IM; Valiyeva F; Encarnación-Rosado J; Roman A; Flores J; Marcos-Martínez MJ; Vivas-Mejía PE Oncotarget; 2016 Jun; 7(24):36321-36337. PubMed ID: 27166999 [TBL] [Abstract][Full Text] [Related]
16. Suppressing miR-199a-3p by promoter methylation contributes to tumor aggressiveness and cisplatin resistance of ovarian cancer through promoting DDR1 expression. Deng Y; Zhao F; Hui L; Li X; Zhang D; Lin W; Chen Z; Ning Y J Ovarian Res; 2017 Jul; 10(1):50. PubMed ID: 28743276 [TBL] [Abstract][Full Text] [Related]
17. Expression profiles of 290 ESTs mapped to chromosome 3 in human epithelial ovarian cancer cell lines using DNA expression oligonucleotide microarrays. Manderson EN; Mes-Masson AM; Novak J; Lee PD; Provencher D; Hudson TJ; Tonin PN Genome Res; 2002 Jan; 12(1):112-21. PubMed ID: 11779836 [TBL] [Abstract][Full Text] [Related]
18. MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1. Sun KX; Jiao JW; Chen S; Liu BL; Zhao Y J Ovarian Res; 2015 Dec; 8():80. PubMed ID: 26626440 [TBL] [Abstract][Full Text] [Related]
19. MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B. Xiao F; Li Y; Wan Y; Xue M Cancer Chemother Pharmacol; 2018 May; 81(5):935-947. PubMed ID: 29594361 [TBL] [Abstract][Full Text] [Related]
20. Ginsenoside 20(S)-Rg3 Inhibits the Warburg Effect Via Modulating DNMT3A/ MiR-532-3p/HK2 Pathway in Ovarian Cancer Cells. Zhou Y; Zheng X; Lu J; Chen W; Li X; Zhao L Cell Physiol Biochem; 2018; 45(6):2548-2559. PubMed ID: 29558748 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]